Larimar Therapeutics (LRMR) Net Income towards Common Stockholders (QoQ) (2013 - 2025)
Larimar Therapeutics (LRMR) Net Income towards Common Stockholders (QoQ) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -26.36% |
| Sep 30, 2025 | -74.90% |
| Jun 30, 2025 | 22.17% |
| Mar 31, 2025 | -18.91% |
| Dec 31, 2024 | -22.01% |
| Sep 30, 2024 | 25.39% |
| Jun 30, 2024 | -24.03% |
| Mar 31, 2024 | 82.21% |
| Dec 31, 2023 | -786.13% |
| Sep 30, 2023 | -5.87% |
| Jun 30, 2023 | -71.41% |
| Mar 31, 2023 | 93.14% |
| Dec 31, 2022 | -1,201.07% |
| Sep 30, 2022 | 2.88% |
| Jun 30, 2022 | 35.72% |
| Mar 31, 2022 | 86.93% |
| Dec 31, 2021 | -575.88% |
| Sep 30, 2021 | 10.23% |
| Jun 30, 2021 | -0.66% |
| Mar 31, 2021 | 83.20% |